GBR 900

Drug Profile

GBR 900

Alternative Names: BXL-1H5; GBR-900; MNAC-13

Latest Information Update: 10 Jun 2014

Price : $50

At a glance

  • Originator Lay Line Genomics
  • Developer Glenmark Pharmaceuticals S.A.
  • Class Analgesics; Monoclonal antibodies
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 04 Jun 2014 Phase-I clinical trials in Pain in United Kingdom (Parenteral)
  • 29 Apr 2014 Glenmark Pharmaceuticals files a Clinical Trial Application with the Medicines and Healthcare Products Regulatory Agency in the United Kingdom for Pain
  • 04 Feb 2013 Preclinical trials in Pain in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top